Pancreatic Cancer Research

ResearcherUniversity of IowaActive in the last 2 years

Garry R. Buettner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5594-1903; OpenAlex author ID A5082072789. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 18

  1. Pharmacologic ascorbate resistant pancreatic cancer demonstrates enhanced metastatic potential. Co-author DOI 10.1016/j.redox.2025.103694↗
  2. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2024.103375↗
  3. Pharmacologic Ascorbate Radiosensitizes Pancreatic Cancer but Radioprotects Normal Tissue: The Role of Oxidative Stress-Induced Lipid Peroxidation. Co-author DOI 10.3390/antiox13030361↗
  4. Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer. Co-author DOI 10.3390/antiox12091683↗
  5. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002086↗
  6. Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate. Co-author DOI 10.3390/antiox10040614↗
  7. Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. Last author DOI 10.1158/1541-7786.mcr-19-0381↗
  8. Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Co-author DOI 10.1667/rr15189.1↗
  9. Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10585-018-9876-z↗
  10. Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1680↗
  11. Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer. Co-author DOI 10.1016/j.freeradbiomed.2015.02.018↗
  12. Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-14-1707↗
  13. Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-1959↗
  14. Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer. Co-author DOI 10.1016/j.freeradbiomed.2014.02.002↗
  15. Regulation of pancreatic cancer growth by superoxide. Co-author DOI 10.1002/mc.21891↗
  16. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗
  17. Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Last author DOI 10.1016/j.redox.2013.11.005↗
  18. Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance. Last author DOI 10.1016/j.freeradbiomed.2011.03.030↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph J. Cullen · 17 shared papers, 2011–2025 · strength 1.81
  2. Brianne R. O’Leary · 9 shared papers, 2015–2025 · strength 1.31
  3. Juan Du · 14 shared papers, 2013–2024 · strength 1.30
  4. Garett J. Steers · 4 shared papers, 2021–2024 · strength 0.73
  5. Bryan G. Allen · 4 shared papers, 2015–2024 · strength 0.31
  6. Juan Du · 1 shared paper, 2025 · strength 0.30
  7. Amanda N. Pope · 1 shared paper, 2025 · strength 0.30
  8. Prabhat C. Goswami · 3 shared papers, 2014–2023 · strength 0.27
  9. Daniel Berg · 3 shared papers, 2013–2024 · strength 0.26
  10. Kellie L. Bodeker · 3 shared papers, 2013–2024 · strength 0.26
  11. Gloria Y. Chen · 1 shared paper, 2024 · strength 0.24
  12. Matthew S. Alexander · 3 shared papers, 2018–2019 · strength 0.24
  13. Justin G. Wilkes · 3 shared papers, 2018–2019 · strength 0.24
  14. John Michael Buatti · 2 shared papers, 2018–2024 · strength 0.23
  15. Douglas Robert Spitz · 4 shared papers, 2011–2018 · strength 0.19
  16. Naomi H. Fei · 1 shared paper, 2024 · strength 0.16
  17. Chandrikha Chandrasekharan MD · 1 shared paper, 2024 · strength 0.16
  18. Mandana Kamgar · 1 shared paper, 2024 · strength 0.16
  19. Joseph Michael Caster · 1 shared paper, 2024 · strength 0.16
  20. Zita A. Sibenaller · 3 shared papers, 2014–2018 · strength 0.16
  21. John A. Cieslak · 3 shared papers, 2014–2015 · strength 0.13
  22. Susan Tsai · 2 shared papers, 2015–2018 · strength 0.12
  23. Jessemae L. Welsh · 3 shared papers, 2013–2015 · strength 0.11
  24. Visarut Buranasudja · 1 shared paper, 2019 · strength 0.10
  25. Rosa F. Hwang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.